The onco-embryonic antigen ROR1 is a target of chimeric antigen T cells for colorectal cancer.

Shangsen Meng,Yao Yao,Peng Li,Le Qin,Qiting Wu,Diwei Zheng,Youguo Long,Yanlai Tang,Dongmei Chen,Ming Li,Zhaoyang Tang,Heng Jia,Xuequn Luo,Di Wu,Lihua Yang,Jiang Lv

doi:10.1016/j.intimp.2023.110402

The onco-embryonic antigen ROR1 is a target of chimeric antigen T cells for colorectal cancer.

Shangsen Meng, Yao Yao + Show 14 more

https://doi.org/10.1016/j.intimp.2023.110402

Copy DOI

Journal: International immunopharmacology	Publication Date: Aug 1, 2023
Citations: 1

Affiliation: Guangzhou Institutes of Biomedicine and Health, State Key Laboratory of Respiratory Disease, Chinese Academy of Sciences, University of Science and Technology of China, Chinese University of Hong Kong, Guangzhou Medical University, First Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Anhui University, Zhujiang Hospital

#Colorectal Cancer #Postoperative Quality Of Life + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Colorectal cancer is globally ranked second in both incidence and mortality rate. It usually develops during the middle or late stages of diagnosis, and is characterized by easy metastasis, poor prognosis, and a significant decline in postoperative quality of life. ROR1 is an excellent oncoembryonic antigen in numerous immunotherapy treatments for tumors. Additionally, it is overexpressed in colorectal cancer. To fill the void in CRC treatment with ROR1 as a target of CAR-T immunotherapy, we designed and prepared antiROR1-CART. This third-generation CAR-T cell can effectively inhibit the growth of colorectal cancer in vitro and in vivo.

Full Text